Volume 13, Number 12—December 2007
Human Papillomavirus Vaccination Strategies
|18-y-old women + 18–24-y-old female catch-up||$73,553,847||2,699,192||$894,545||481||$1,860|
|15-y-old girls + 15–24-y-old female catch-up||$73,895,046||2,699,214||$341,199||22||$15,509|
|12-y-old girls and boys||$78,707,825||2,699,327||$4,812,779||113||Dominated|
|12-y-old girls + 12–24-y-old female catch-up||$74,815,667||2,699,343||$920,621||129||$7,137|
|18-y-old women and men + 18–24-y-old female and male catch-up||$77,535,383||2,699,385||$2,719,716||42||$64,755|
|15-y-old girls and boys + 15–24-y-old female and male catch-up||$78,455,750||2,699,404||$920,367||19||$48,440|
|12-y-old girls and boys + 12–24-y-old female catch-up||$79,746,357||2,699,461||$1,290,607||57||$22,642|
|12-y-old girls and boys + 12–24-y-old female and male catch-up||$81,761,210||2,699,506||$2,014,853||45||$44,775|
*QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; $, US dollars.
†Based on discounted costs reported by Elbasha et al. (1).
‡Compared with the preceding nondominated strategy. Strategy A is dominated if there exists another strategy, B, that is more effective and less costly than strategy A.